Polylaminin
Polylaminin or polyLM, is a stabilized form of laminin, a family of natural proteins, which is being studied for use in treating spinal cord injuries in animals and humans. In early human trials, a patient with a fractured neck vertebra after a car accident had a full recovery after a year, and a chronic quadriplegic patient regained arm movement. The Brazilian Academy of Neurology, Brazilian Academy of Sciences, and the Brazilian Society for the Progress of Science advise caution before clinical tests are completed.
References
- ↑ Marques, Jairo; Pasquini, Patrícia (9 November 2025). "Groundbreaking Brazilian Drug, Considered Capable of Reversing Spinal Cord Injury, Presented in São Paulo". Folha de S.Paulo. Retrieved 2 March 2026.
- ↑ Menezes, Karla; Lima, Marco Aurelio B.; et al. (21 February 2024). "Return of Voluntary Motor Contraction After Complete Spinal Cord Injury: A Pilot Human Study on Polylaminin". medRxiv 10.1101/2024.02.19.24301010v1.
- ↑ "Brazilian scientists use placenta protein to restore some movement in dogs and humans with spinal cord injuries".
- ↑ de Carvalho, Ana Luiza (11 September 2025). "Cristália drug offers hope for quadriplegia patients". Valor International. Retrieved 2 March 2026.
- ↑ National Cancer Institute (4 April 2023). "The case of polylaminin in the treatment of spinal cord injuries". YouTube. Retrieved 3 October 2025.
- ↑ National Cancer Institute (30 October 2025). "Polylaminin: The Brazilian discovery that could transform the treatment of spinal cord injuries". YouTube. Retrieved 3 October 2025.
- ↑ Collucci, Cláudia (24 February 2026). "Neurologists Warn of Lack of Evidence Regarding Polylaminin's Action in Spinal Cord Injury". Folha de S.Paulo. Retrieved 1 March 2026.
 | This protein-related article is a stub. You can help Wikipedia by adding missing information. |